Intellia Therapeutics - investor relations

Skip to main navigation

invest in
partner in
jo in
in fo
CRISPR/CAS9
pipel in e
get in touch
news & resources

stock information

Copyright Nasdaq. Minimum 15 minutes delayed.

press releases

–

May 17, 2018

Summary Toggle Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting

events and presentation

upcoming event

Jun 20, 2018
8:00 AM EDT

Panel Discussion: Gene Editing: From Science to Reality

corporate governance

corporate governance

financial information

financial information

stock<br />
information

stock
information

investor<br />
FAQs

investor
FAQs

information<br />
request

information
request

IR<br />
contacts

IR & PR
contacts

analyst coverage

invest in

Investor Relations

investor relations
press releases
events & presentations
corporate governance
financial information
stock information
analyst coverage
investor FAQs
information request
IR & PR contacts

partner in

partnering
our partners
who to contact

jo in

we’re in
i’m in
join in

CRISPR/Cas9

transforming technology
how CRISPR/Cas9 works
strategy
types of edits
delivery of CRISPR/Cas9

pipel in e

in fo

overview
leadership
eXtellia

get in touch

© Intellia Therapeutics 2018

terms of use

Menu